key: cord-0869906-8fnjmj7k
authors: Dodd, William S.; Jabbour, Pascal M.; Sweid, Ahmad; Tjoumakaris, Stavropoula; Gooch, Michael R.; Al Saiegh, Fadi; Hasan, David M.; Starke, Robert M.; Kan, Peter T.; Polifka, Adam J.; Laurent, Dimitri; Busl, Katharina M.; Ghosh, Ritam; Hoh, Brian L.; Chalouhi, Nohra
title: Aneurysmal Subarachnoid Hemorrhage in COVID-19 Patients: A Case Series
date: 2021-07-07
journal: World Neurosurg
DOI: 10.1016/j.wneu.2021.06.092
sha: 1b773e0607fb646190d990f1424a60fe3600db7e
doc_id: 869906
cord_uid: 8fnjmj7k

Objective The SARS-CoV-2 pandemic is a pressing public health issue. While most cases do not result in severe illness requiring hospitalization, there is increasing evidence that SARS-CoV-2-induced inflammation can exacerbate preexisting diseases. We sought to describe the characteristics of aneurysmal subarachnoid hemorrhage patients who were actively or very recently infected with SARS-CoV-2. Methods We reviewed subarachnoid hemorrhage cases of patients who were also SARS-CoV-2-positive at five high-volume cerebrovascular centers in the U.S from March 2020 to January 2021. Cases of aneurysmal subarachnoid hemorrhage were analyzed. Results A total of ten patients were identified, consisting of five women (50%) and five men (50%). Median age was 38.5 years. Four of the ten patients (40%) were asymptomatic with respect to SARS-CoV-2-related symptoms, three patients (30%) had mild-to-moderate symptoms, and three patients (30%) had severe COVID, with pneumonia and sepsis. Of the ten cases, four had dissecting pseudoaneurysms (40%), three in the posterior circulation and one in the anterior circulation. Among six saccular/blister aneurysms, four (67%) were ≤4 mm in largest diameter. Conclusions Our experience with aneurysmal subarachnoid hemorrhage in COVID-positive patients reveals a possibly distinct pattern compared to traditional aneurysmal subarachnoid hemorrhage, namely a high frequency of small aneurysms, dissecting pseudoaneurysms, and young patients.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), named due to its ~80% 26 genetic similarity with the original SARS coronavirus, 1 is a novel betacoronavirus that initiated the 27 "COVID-19" pandemic. Like other coronaviruses, SARS-CoV2 has been show to be able to 28

invade the central nervous system via various routes, possesses neurotropism and is 29 J o u r n a l P r e -p r o o f neurovirulent. 2 There have been over 175 million SARS-CoV-2/COVID-19 infections to date, 3 with 1 outcomes ranging from asymptomatic infection to multi-organ failure and death. The spectrum of 2 disease severity following SARS-CoV-2 infection is a function of host immune response. 3

Ineffective immune response can lead to exacerbated stimulation of innate immune cells, 4 maladaptive inflammation, and development of the so-called "cytokine storm". 4 What remains 5 unclear however, is the full extent to which SARS-CoV-2 infection affects extrathoracic organs 6 and the interactions between COVID-induced inflammation and preexisting comorbidities. Central 7 nervous system complications have been reported in as many as 38% of patients with varying 8 degrees of severity. 5 There are accumulating reports of increased cerebrovascular injury 6 and 9 ischemic stroke 7 in COVID-19 patients, but reports on subarachnoid hemorrhage and cerebral 10 aneurysm rupture are limited to few case reports with largely non-aneurysmal subarachnoid 11 hemorrhage and only one reported aneurysmal subarachnoid hemorrhage to date. 8 12

The prevalence of cerebral aneurysms in the adult population is estimated to be between 13 2-4%. 9,10 Most cerebral aneurysms are saccular in morphology while fusiform, blister, & dissecting 14 pseudoaneurysms are rare. 11- 13 The risk of an aneurysm rupturing is heavily influenced by risk 15 factors like age, sex, smoking status, hypertension, and aneurysm size, morphology, & location, 16 varying from 0-50% risk of rupture over a 5-year interval. 13 

Data were collected retrospectively from patients treated at five high-volume cerebrovascular 28 centers from March 2020 to January 2021 with a diagnosis of spontaneous subarachnoid 29 hemorrhage. Patients with a confirmed aneurysmal rupture and a diagnosis of SARS-CoV-2 30 infection (made based on RT-qPCR testing of a nasopharyngeal swab sample from each patient 31 J o u r n a l P r e -p r o o f during hospital admission and up to 28 days prior to admission following standard protocols 21,22 ) 1 were included in the final analysis. The following data were collected from each patient's record: 2 age, sex, aneurysm type, aneurysm location, Hunt & Hess classification, presenting symptoms, 3 COVID symptoms, aneurysm treatment, length of stay, modified Rankin scale (mRS) at 4 discharge, history of hypertension, history of diabetes, history of cerebral aneurysms, history of 5 chronic heart disease, and history of chronic lung disease. To preserve patient anonymity and in 6 compliance with Institutional Review Board regulations, we do not present the full data for 7 individual cases and instead report the aggregated data or individual deidentified data points. 8

Patient Characteristics and Presentation 10

There were a total of ten patients. Patient characteristics are summarized in Table 1 . There 11 were five women (50%) and five men (50%). The median age was 38.5 years old (IQR: 36.5 -45 12 years, range: 29 -57 years). All ten patients tested positive for COVID-19 when the subarachnoid 13 hemorrhage (SAH) occurred. Four of the ten patients (40%) were asymptomatic with respect to 14 COVID-19-related symptoms, testing positive for the virus upon admission for aneurysmal SAH 15 (aSAH). Three patients (30%) had mild-to-moderate symptoms, including cough, sore throat, 16 and/or low-grade fever. The remaining three patients (30%) had severe cases; all three were 17 diagnosed with pneumonia and sepsis and one patient also suffered acute kidney injury. One 18 patient had recovered from COVID-19-pneumonia and sepsis before developing aSAH two weeks 19 later. The patient was still positive for COVID-19 at the time of the hemorrhage. No patient had a 20 documented history of chronic lung disease or chronic heart disease. Interestingly, one patient 21 with a dissecting pseudoaneurysm of the right vertebral artery had a brain MRI study from 2005 22 that showed no evidence of aneurysm at that time ( Figure 1) . 23

Hunt and Hess grades were as follows: grade II, three patients (30%); grade III, three 24 patients (30%); grade IV, three patients (30%); grade V, one patient (10%) ( Table 1) . 25

Of the ten cases reviewed, there were five saccular aneurysms (50%), one blister-type 27 aneurysm (10%), and four dissecting pseudoaneurysms (40%). Of note, one patient expired prior 28 to obtaining a cerebral angiogram but imaging was highly suspicious for a dissecting 29 pseudoaneurysm of the left posterior cerebral artery. The saccular aneurysms were 3, 3, 4, 15, 30 and 19 mm in diameter while the blister aneurysm was only 1.5 mm. The dissecting 1 pseudoaneurysms were 5, 6, 15, and 21 mm in diameter. 2 Aneurysm location, type, and treatment are summarized in Table 2 . Seven aneurysms 3 (70%) occurred in the anterior circulation (three in the anterior communicating artery, one in the 4 middle cerebral artery, one in the posterior communicating segment, one in the ophthalmic 5 segment, and one anterior choroidal aneurysm) and three (30%) occurred in the vertebro-basilar 6 system (all three were dissecting pseudoaneurysms; one in the posterior cerebral artery, one in 7 the posterior inferior cerebellar artery, and one in the vertebral artery). Three aneurysms were 8 treated with endovascular coiling, three with microsurgical clipping, and three with flow diversion. 9

One patient who presented with a poor neurologic exam and did not improve after a 10 decompressive hemicraniectomy expired without undergoing aneurysm treatment. 11

One patient developed cerebral vasospasm and delayed cerebral ischemia and 13 underwent infusion of intraarterial verapamil. Another patient underwent evacuation of a post-14 operative hematoma following microsurgical clipping. Clinical outcomes at discharge were as 15 follows: mRS 0-2 in seven patients (70%); mRS 3 in one patient (10%), and mRS 6 in two patients 16 (20%) ( Table 1) . Both patients who expired presented with high-grade SAH, did not improve after 17 several days, and eventually were transitioned to end-of-life care. 18

The influence of SARS-CoV-2 infection on cerebral aneurysm pathology and rupture risk 20 is unknown. In this study, we describe the clinical characteristics of SARS-CoV-2-positive aSAH 21 patients. Prospective cohort and natural history studies demonstrate propensity for aneurysmal 22 rupture to occur in patients older than 50 years of age. 23, 24 In this case series, eight of ten patients 23 (80%) were under 50 years of age. In contrast, in the International Subarachnoid Aneurysm Trial 24 (ISAT), only about 40% of patients were under 50 years of age. 25 Likewise, in the Barrow ruptured 25 aneurysm trial, the mean age was 53 years old in the clip group and 54 years old in the coil 26 group. 24 27 Saccular aneurysms are the most common culprits of aSAH (up to 90% of cases) and 28 large size increases rupture risk. 13, 26 Of the six cases of saccular/blister aneurysms reviewed at 29 our institutions, there were four that were 4 mm in diameter or less. The expected rupture rate for 30 saccular aneurysms <5 mm in size is exceedingly low, less than 1% over a 5-year interval. 13 While 31 J o u r n a l P r e -p r o o f small aneurysms can rupture, 27 it is noteworthy to have such a high proportion of very small 1 aneurysms (1.5 mm, 3 mm, 3 mm, and 4 mm) in a small series. 2

Our study also includes four dissecting pseudoaneurysms and one blister aneurysm, 3 together representing 50% of the cases. Dissecting and blister aneurysms are less common 4 causes of aSAH than saccular aneurysms. 11 Precise estimates are difficult, but most studies 5 report dissecting pseudoaneurysms and blister aneurysms to each represent approximately only 6 1% of cerebral aneurysms, 28-32 therefore it is noteworthy to have such a high frequency of these 7

lesions in a small case series. The pathophysiology of dissecting pseudoaneurysms differs from 8 saccular aneurysms as it involves a defect in the internal elastic lamina followed by mural 9 dissection and pseudoaneurysm formation. The potential association seen in this series between 10 COVID-19 and dissecting pseudoaneurysms could be interesting but it remains to be seen how 11

COVID-19 could contribute to intracranial artery dissection and pseudoaneurysm formation. 12

The influence of the COVID-19 pandemic on access and delivery of healthcare is a 13 potentially influential variable in our study. There was a decrease in admissions for SAH and 14 other hand, it is reassuring that the outcomes in our cases do not seem to differ from what is 20 expected with aSAH. Three of ten patients had an mRS of > 2 at discharge, which is consistent 21 with existing literature. 24 22

The current study is not designed to establish a causality between COVD-19 and cerebral 23 aneurysm rupture; instead, it is meant to describe and analyze the characteristics of ruptured 24 aneurysms in COVID-19 patients. Given the high incidence of small aneurysm ruptures in young 25 patients in this series, one could speculate thatin a subset of patients-the inflammatory 26 response accompanying COVID-19 may cause the premature rupture of preexisting saccular 27 cerebral aneurysms that would have otherwise ruptured at a later age when they have grown 28 larger in size. We suggest that any relationship between SARS-CoV-2 infection and cerebral 29 aneurysm rupture could possibly involve macrophage-mediated production of IL-1β, IL-6, and 30

TNFα. Macrophages are actually highly implicated in both aneurysmal rupture and COVID-19-31 related inflammations. 17, 37, 38 This remains, however, purely speculative and warrants additional 32 investigation. A larger sample of aSAH patients and measurement of inflammatory mediators 33 J o u r n a l P r e -p r o o f would be especially valuable in defining the association between SARS-CoV-2 infection and 1 aSAH. 2

Over one year into the COVID-19 pandemic, the global community is constantly 4 discovering sequelae of SARS-CoV-2 infection. In this case series, we report ten aSAH cases 5 that occurred in SARS-CoV-2-positive patients. These cases are the first case series of this 6 specific phenomenon and they raise questions on a possible interaction between SARS-CoV-2 7 infection and cerebral aneurysm rupture. The atypical features, namely small size, presence of 8 dissection, and young age deserve further study. showing a dissecting aneurysm of the V4 segment of the right vertebral artery before and after 7 successful treatment with FRED-assisted coiling. 8 J o u r n a l P r e -p r o o f 

Impact of the COVID-19 Pandemic on 16

Traumatic intracranial 21 aneurysms

Pathological inflammation in patients with COVID-19: a key role for 23 monocytes and macrophages

The landscape of lung bronchoalveolar immune cells in

COVID-19 revealed by single-cell RNA sequencing

Severe Acute Respiratory Syndrome-Coronavirus-2, (a)SAH: (aneurysmal) Subarachnoid Hemorrhage, ACE2: Angiotensin Converting Enzyme Type 2, ARDS: Acute Respiratory Distress Syndrome, RT-qPCR: Reverse Transcriptase-Quantitative Polymerase Chain Reaction, mRS: Modified Rankin Scale, IQR: Interquartile Range, ISAT: International Subarachnoid Aneurysm Trial, IL-1β: Interleukin 1-Beta, IL-6: Interleukin 6, TNFα: Tumor Necrosis Factor Alpha, CT: Computed Tomography, MRA: Magnetic Resonance Angiography, FRED: Flow Redirection Endoluminal Device, IVH: Interventricular Hemorrhage

The authors hereby certify that, to the best of our knowledge, no aspect of our current personal or professional circumstances place any of us in the position of having a conflict of interest with any element of this manuscript.